On account of such networking between receptor systems, a GABRB2-origin of schizophrenia is entirely compatible with drug development against the disease targeting widely at the dopamine, glutamate, GABA, acetylcholine, serotonin, and hormonal systems, necessitated particularly by the shortfall of effective medications for the negative symptoms and cognitive deficits75,76. This evidence concerns the gene GABRB2 and schizophrenia.